Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies

被引:599
作者
Harris, CC [1 ]
机构
[1] NCI, HUMAN CARCINOGENESIS LAB, DIV BASIC SCI, BETHESDA, MD 20892 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1996年 / 88卷 / 20期
关键词
D O I
10.1093/jnci/88.20.1442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The p53 tumor suppressor protein is involved in multiple central cellular processes, including transcription, DNA repair, genomic stability, senescence, cell cycle control, and apoptosis. p53 is functionally inactivated by structural mutations, interaction with viral products, and endogenous cellular mechanisms in the majority of human cancers. This functional inactivation can, in some circumstances, produce resistance to DNA-damaging agents commonly used in cancer chemotherapy and radiotherapeutic approaches. Current research is defining the biochemical pathways through which p53 induces cell cycle arrest and apoptosis, Knowledge of these fundamental processes is leading to the identification of molecular targets toward which multimodality cancer therapies, using chemotherapeutic, immunotherapeutic, and gene-therapeutic strategies, can be based.
引用
收藏
页码:1442 / 1455
页数:14
相关论文
共 290 条
  • [91] MUTANT-P53 CAN INDUCE TUMORIGENIC CONVERSION OF HUMAN BRONCHIAL EPITHELIAL-CELLS AND REDUCE THEIR RESPONSIVENESS TO A NEGATIVE GROWTH-FACTOR, TRANSFORMING GROWTH FACTOR-BETA(1)
    GERWIN, BI
    SPILLARE, E
    FORRESTER, K
    LEHMAN, TA
    KISPERT, J
    WELSH, JA
    PFEIFER, AMA
    LECHNER, JF
    BAKER, SJ
    VOGELSTEIN, B
    HARRIS, CC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) : 2759 - 2763
  • [92] Modulation of DNA topoisomerase I activity by p53
    Gobert, C
    Bracco, L
    Rossi, F
    Olivier, M
    Tazi, J
    Lavelle, F
    Larsen, AK
    Riou, JF
    [J]. BIOCHEMISTRY, 1996, 35 (18) : 5778 - 5786
  • [93] AMPLIFICATION OF THE DIHYDROFOLATE-REDUCTASE GENE IS A MECHANISM OF ACQUIRED-RESISTANCE TO METHOTREXATE IN PATIENTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA AND IS CORRELATED WITH P53 GENE-MUTATIONS
    GOKER, E
    WALTHAM, M
    KHERADPOUR, A
    TRIPPETT, T
    MAZUMDAR, M
    ELISSEYEFF, Y
    SCHNIEDERS, B
    STEINHERZ, P
    TAN, C
    BERMAN, E
    BERTINO, JR
    [J]. BLOOD, 1995, 86 (02) : 677 - 684
  • [94] CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS - UP-REGULATION OF P53 GENE-EXPRESSION AND INDUCTION OF APOPTOSIS BY TUMOR-NECROSIS-FACTOR-ALPHA
    GOTLIEB, WH
    WATSON, JM
    REZAI, A
    JOHNSON, M
    MARTINEZMAZA, O
    BEREK, JS
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 170 (04) : 1121 - 1130
  • [95] DOWN-REGULATION OF WILD-TYPE P53 ACTIVITY INTERFERES WITH APOPTOSIS OF IL-3-DEPENDENT HEMATOPOIETIC-CELLS FOLLOWING IL-3 WITHDRAWAL
    GOTTLIEB, E
    HAFFNER, R
    VONRUDEN, T
    WAGNER, EF
    OREN, M
    [J]. EMBO JOURNAL, 1994, 13 (06) : 1368 - 1374
  • [96] Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
    Graeber, TG
    Osmanian, C
    Jacks, T
    Housman, DE
    Koch, CJ
    Lowe, SW
    Giaccia, AJ
    [J]. NATURE, 1996, 379 (6560) : 88 - 91
  • [97] GREENBLATT MS, 1994, CANCER RES, V54, P4855
  • [98] Greenblatt MS, 1996, CANCER RES, V56, P2130
  • [99] Greenblatt MS, 1995, CANCER SURV, V25, P293
  • [100] GUILLOUF C, 1995, ONCOGENE, V10, P2263